Information Provided By: 
Fly News Breaks for June 28, 2016
ALKS
Jun 28, 2016 | 07:46 EDT
Leerink analyst Paul Matteis lowered his price target for Alkermes to $54 from $58 citing the company's base business progress, its 5461 data and a changing landscape in Multiple Sclerosis. However, the analyst still sees multiple points of optimism, including a bullish take on the company's Vivitrol, where consensus numbers seem too low to him, and an "encouraging" take on the value proposition for its 3831 in schizophrenia. Matteis reiterates an Outperform rating on the shares.
News For ALKS From the Last 2 Days
